MRI for staging of rectal carcinoma

Newton S, Merlin T, Hedayati H, Sullivan T, Street J, Hiller JE
Record ID 32012000218
Original Title: Application 1110
Authors' results and conclusions: Safety-No physical harms were reported as resulting directly from the MRI staging procedure or the comparative staging techniques. Harms are very rare provided suitable precautions are taken. However, patients must be screened for ferromagnetic or electrical implants prior to a MRI, as they may dislodge or become disrupted by the strong magnetic fields. A small proportion of patients will suffer from claustrophobia and so find the MRI procedure distressing. Harms may arise as a result of incorrect staging, so safety is linked to the accuracy of the staging techniques. Effectiveness-There was very little evidence comparing the accuracy of MRI against other forms of preoperative imaging. On the basis of one study per comparison, MRI and multi-slice computed tomography (MSCT) appear to have similar accuracy for predicting T stage and N stage, while MRI was more accurate at predicting N stage than either conventional CT along or endorectal ultrasound (ERUS). The expert opinion of the Advisory Panel is that MRI provides superior contrast resolution to MSCT and is more effective at defining the circumferential resection margin. Use of MRI to determine whether patients should receive neoadjuvant therapy or proceed to primary surgery is likely to result in an increased number of patients being recommended for primary surgery when compared to patients staged by conventional CT or ERUS (assuming that patients would otherwise receive neoadjuvant therapy). Economics-It is estimated that funding MRI for newly diagnosed patients would cost $1,162,024 to society, of which $1,103,174 would be borne by the Australian Government. It is possible that the additional costs would be counteracted by less use of neoadjuvant therapy. The cost offset to the Australian Government of reduced neoadjuvant therapy is estimated to be $1,512,661 per year. If the cost savings from reduced neoadjuvant therapy use are used to offset the costs of MRI, there would be an overall cost saving of $499,487 to the Australian Government and $5,636,565 to society.
Project Status: Completed
Year Published: 2008
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Australia
MeSH Terms
  • Rectal Neoplasms
  • Neoplasm Staging
  • Magnetic Resonance Imaging
Organisation Name: Adelaide Health Technology Assessment
Contact Address: School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
Contact Email:
Copyright: Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.